KAHR’s drug development pipeline is built around the 'Dual Signaling Proteins (DSP) technology, also known as 'Signal Converter Proteins' (SCP), the outgrowth of research carried out for over 17 years at the University of Pennsylvania and the Hadassah Medical Center. The results of these research efforts have been published in multiple scientific publications.
DSP molecules are mostly constructed around the TNF-superfamily, the family of factors that manage our immune system, and are especially effective in targeting complex biological processes within the immune system.
DSP molecules are fusion proteins connecting an extracellular portion of a Type-I membrane protein (at the fusion protein’s N-terminus) with an extracellular portion of a Type-II membrane protein (at the fusion protein’s C-terminus). This enhanced architecture of DSP molecules creates fusion-proteins with two functional ends that allow the chimeric (fused) molecule to facilitate a unique higher structure and mode-of-action with increased activity, specificity, and therapeutic benefits that cannot be achieved by simply administering the DSP protein elements as separate units.
With two functional ends, DSP drugs are capable of effecting two biological pathways at the same time and at the same place with both pathways reinforcing each other. This breakthrough has immediate implications for the treatment of diseases in which the natural ligands of the DSP molecules are on the same cell or in close proximity, such as in cancer and in autoimmune disease.
KAHR's DSP technology is divided into two proprietary platforms; the DSP-Hexamers and the DSP-Clusters, each covering hundreds of different drug candidates. KAHR Medical has selected two promising DSP candidates for its current drug development pipeline; KAHR-101,representing the DSP-Clusters, and KAHR-102, representing the DSP-Hexamers. Both programs are currently in development towards clinical studies for the treatment of different cancers and autoimmune diseases.